MedTrace Logo

Prostaglandin Inhibition for Emphysema

NCT02006576 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2023-12-13

Study results available
· View outcomes & findings →

Summary

The Prostaglandin Inhibition for Emphysema (PIE) study will determine if a currently available therapy, ibuprofen 600 mg three times daily, can block PGE production in the lower respiratory tract and if this results in improvement in measures of lung repair function.

Conditions

  • Emphysema

Interventions

DRUG

600 mg ibuprofen three times daily for 48 weeks

OTHER

Placebo three times daily

Sponsors & Collaborators

  • National Jewish Health

    collaborator OTHER

  • Temple University

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • University of Nebraska

    lead OTHER

Principal Investigators

  • Stephen I Rennard, MD · University of Nebraska

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
46 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-01-01
Primary Completion
2018-03-31
Completion
2018-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02006576 on ClinicalTrials.gov